Navigation Links
Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations
Date:4/3/2008

- Chairman and CEO Honors the Anniversary by Ringing The Closing Bell(R) at

the NYSE on April 4 -

IRVINE, Calif., April 3, 2008 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation (NYSE: EW), a world leader in products and technologies to treat advanced cardiovascular disease, today announced its 50th anniversary of partnering with clinicians to develop life-saving innovations. To celebrate its five decades of innovation and success, and eight years as an independent company, Michael A. Mussallem, Edwards' chairman and CEO, will visit the New York Stock Exchange (NYSE) tomorrow afternoon to ring The Closing Bell(R), signaling the end of the trading week. A live webcast of The Closing Bell(R) will be available at http://www.nyse.com beginning at 3:55 p.m. EDT on April 4, 2008.

Edwards' 50-year history dates back to 1958, with the development of the first commercially available artificial heart valve by Miles "Lowell" Edwards and Dr. Albert Starr. The company built on this legacy by innovating a number of other pioneering products including the first -- and only -- biomechanically engineered tissue heart valve; the first heart valve repair ring; the first embolectomy catheter to remove obstructions in blood vessels; the first pulmonary artery catheter, which established the foundation for hemodynamic monitoring; and more recently, the first "beating heart" transcatheter aortic valve replacement.

"We take great pride in our 50-year heritage of working as trusted partners with clinicians to develop innovative technologies that transform patient care," said Mussallem. "We believe Lowell Edwards would be very proud of the company that bears his name today and the more than 5,600 employees worldwide who carry on his mission to provide treatments and hope for patients with advanced cardiovascular disease."

"It brings me tremendous joy that the replacement heart valves Lowell Edwards and I co-developed 50 years ago began a company that today continues to pioneer live-saving cardiovascular devices and procedures," said Dr. Albert Starr, medical director of the Providence Heart and Vascular Institute and co-recipient of a 2007 Lasker Award for the development of artificial heart valves. "I'm proud of my enduring association with Edwards Lifesciences and look forward to the company's continued success helping millions of patients worldwide."

In 1958, Lowell Edwards was a 60-year-old recently retired engineer with 63 patents in an array of industries, an entrepreneurial spirit and dreams of helping patients with heart disease. With a background in hydraulics and fuel pump operations, he believed the human heart could be mechanized. He presented the concept to Dr. Starr, a young surgeon at the University of Oregon Medical School, who encouraged Lowell Edwards to focus first on developing an artificial heart valve, for which there was an immediate need. After only two years, the first Starr-Edwards mitral valve was designed, developed, tested and successfully placed in a patient.

About Edwards Lifesciences

Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards treats advanced cardiovascular disease with its market-leading heart valve therapies, and critical care and vascular technologies. In 2008, Edwards celebrates 50 years of partnering with clinicians to develop life-saving innovations. The company's global brands, which are sold in approximately 100 countries, include CardioVations, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at http://www.edwards.com.

Edwards is a trademark of Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E logo, CardioVations, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office. The Closing Bell is a registered trademark of the New York Stock Exchange, Inc.


'/>"/>
SOURCE Edwards Lifesciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Lambert, Edwards & Associates Named Agency of Record for The West Michigan Science & Technology Initiative
2. Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve
3. Edwards Lifesciences Announces Organizational Changes
4. Edwards Lifesciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
5. Edwards Lifesciences to Host Earnings Conference Call on February 5, 2008
6. Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve
7. Edwards Lifesciences Completes Acquisition of CardioVations Product Line
8. Edwards Lifesciences Forecasts Strong Growth in 2008
9. Marshall Edwards, Inc. to Present at BIO Investor Forum 2007
10. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
11. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... prevention of migraine at the American Academy of Neurology ... 2017, in Boston . ... safety and patient outcomes data for galcanezumab in patients ... monthly migraine headache days among patients with episodic migraine. ...
(Date:4/20/2017)... ... April 20, 2017 , ... ... scientific and clinical research community’s growing body of knowledge during its Eighth ... Gracie Theatre and the adjacent Darling Atrium. During the event, undergraduates, graduate students, ...
(Date:4/20/2017)... 20, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: ... the International Liver Congress ("ILC") 2017 of the European Association ... Amsterdam on the positive effects of PBI-4050 on ... obesity and metabolic syndrome. ... According to Dr. Lyne Gagnon, Vice-President of R&D Pre-clinical of ...
(Date:4/20/2017)... ... 20, 2017 , ... Parallel6™ , the leader in mClinical™ technologies for ... were named one of the 2017 Top 10 eClinical Trial Management Solution Providers ... industry. , “We take pride in honoring Parallel6 as one of the top 10 ...
Breaking Biology Technology:
(Date:3/20/2017)... March 20, 2017 At this year,s CeBIT Chancellor ... biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together with ... this year,s CeBIT partner country. At the largest German biometrics company the ... fingerprint, face and iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/16/2017)... 2017 CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity ... Used combined in one project, multi-biometric ... ...
(Date:3/9/2017)... Australia , March 9, 2017 /PRNewswire/ ... at the prestigious World Lung Imaging Workshop at the ... Fouras , was invited to deliver the latest data ... This globally recognised event brings together leaders at the ... latest developments in lung imaging. "The ...
Breaking Biology News(10 mins):